ClinicalTrials.gg
CompletedNCT06713590Updated Jun 25, 2025

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

A Phase 1 interventional study of Axatilimab in Healthy Participants, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCA34176
  • Axatilimab
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Aged 18 to 55 years, inclusive, at the time of signing the ICF.
  • within the range of 18.0 to 30.0 kg/m2 (inclusive) at screening.

Note: Participants with a BMI up to 32.0 kg/m2 may be enrolled with the sponsor's approval.

  • Body weight of ≥ 40 kg (inclusive). Note: For each cohort, approximately 6 participants from 1 of each weight band (40-65 kg, > 65-90 kg, > 90 kg) will be enrolled, to total approximately 24 participants in each weight band.
  • No findings on screening evaluations (clinical, , and comprehensive physical examination, including the eyes). No laboratory values out of normal reference ranges.
  • Ability to be administered IV or SC study drug.
  • Willingness to avoid pregnancy or fathering children based on the protocol defined criteria below.

    • Male participants with must agree to take appropriate precautions to avoid fathering children, including refraining from donating sperm, from screening through 90 days (a spermatogenesis cycle) after the dose of study drug on Day 1 and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.
    • Female participants who are must have a negative pregnancy test at screening and a negative pregnancy test at check-in (Day -1) and must agree to take appropriate precautions to avoid pregnancy from screening through 60 days (2 menstrual cycles) after the dose of study drug on Day 1 and must refrain from donating oocytes during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.
    • Female participants not considered to be of childbearing potential as defined in the protocol are eligible and must have a negative pregnancy test at screening and check-in.

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
  • High blood pressure (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening, confirmed by repeat testing).
  • Resting pulse rate \< 40 bpm or > 100 bpm at screening. May repeat up to 3 total measurements, separated by 5 minutes, to confirm.
  • History of rheumatologic/ disorders, except for minor eczema and rosacea.
  • History or presence of an abnormal before initial dose administration that, in the investigator's opinion, is . Participants with a interval > 470 milliseconds, regardless of sex. QRS interval > 120 milliseconds, or PR interval > 220 milliseconds will be excluded. In the event a value is exclusionary, a single ECG will be repeated twice, and an average taken of the 3 readings will be used to determine if a participant should be excluded.
  • History of within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
  • Blood transfusion within 4 months of check-in (Day -1).
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment (includes latent treated tuberculosis).
  • Positive test for , , or . Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
  • Any chronic or recurrent edema. History of urticaria, allergic rhinoconjunctivitis, seasonal atopic, food, and/or latex allergy.
  • Medical or self-reported history of alcoholism within 3 months of screening.
  • History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = one-half pint of beer or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine).
  • Has received a (including attenuated) or anticipation of need for such a vaccine during the study.

Note: No vaccines may be administered within 3 months prior to the first dose of study drug.

  • Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another medication or current enrollment in another investigational drug or investigational product study.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Previous receipt of axatilimab.
  • Known or severe reaction to axatilimab or of axatilimab.
  • Inadequate veins for multiple venous puncture or IV catheter insertion as determined by the investigator or designee.
  • Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  • History of tobacco or nicotine-containing product use within 1 month of screening.
  • Use of prescription drugs (including hormonal ) within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional and standard-dose acetaminophen, ibuprofen, and standard-dose vitamins are permitted. Megadose vitamins or supplements are not permissible.
  • Women who are pregnant or breastfeeding.
  • Any condition that would, in the investigator's judgment: interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • \< 90 mL/min/1.73 m2 based on the site's standard formula at screening. NOTE: assessment of eGFR may be repeated once if outside of the reference range.
  • Excessive exercise beyond the activities of daily living (eg, Ironman®, triathlon, etc) within 7 days before check-in (Day -1).
  • History of keloid or hypertrophic scarring.
  • History of recurrent pneumonia, skin infection, or viral infections within 6 months of screening.
  • History of acute or chronic pancreatitis.
  • History of retinal eye disorders. Presbyopia, myopia, and astigmatism are permitted.
  • Abdominal tattoos, scarring at injection site.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort A

    Axatilimab will be administered at a protocol defined starting dose administered as an IV infusion.

    Drug: Axatilimab

  • Experimental
    Cohort B

    Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.

    Drug: Axatilimab

  • Experimental
    Cohort C

    Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.

    Drug: Axatilimab

  • Experimental
    Cohort D

    Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.

    Drug: Axatilimab

Interventions

  • Axatilimab will be administered at protocol defined dose.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter: Cmax of axatilimab

    Maximum Observed Plasma Concentration of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  2. Pharmacokinetics Parameter: AUC(0-t) of axatilimab

    Area Under the concentration- time curve up to the last measurable concentration of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  3. Pharmacokinetics Parameter: AUC 0-∞ of axatilimab

    Area Under the Concentration-time Curve From 0 to Infinity of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  4. Number of participants with Treatment Emergent Advers Events (TEAE's)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: Up to 3 months

Secondary outcomes

  1. ADA

    Percent of patients with anti-drug antibody (ADA).

    Time frame: Pre dose on Day 1, Post dose Days 8, 15, 22, 28 and 60

  2. Pharmacokinetics Parameter: Tmax of axatilimab

    Time to reach maximum plasma concentration of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  3. Pharmacokinetics Parameter: t1/2 of axatilima

    Apparent terminal phase disposition half-life of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  4. Pharmacokinetics Parameter: CL (or CL/F) of axatilimab

    Dose clearance of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

  5. Pharmacokinetics Parameter: Vz (or Vz/F) of axatilimab

    Volume of distribution of axatilimab.

    Time frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60

07

Study locations

1 site
  • Celerion, Inc
    Tempe, Arizona 85283, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jun 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 3, 2024
StartActual
Jan 14, 2025
Primary completionActual
Jun 6, 2025
CompletionActual
Jun 10, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06713590
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Jan 14, 2025
Primary completion
Jun 6, 2025
Completion
Jun 10, 2025
Last update
Jun 25, 2025

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion